Effective weight-loss pills, including an oral version of Ozempic, are on the horizon

Effective weight-loss pills, including an oral version of Ozempic, are on the horizon

SAN DIEGO — Drugmakers are racing to be the first to market an oral version of the newest class of weight-loss drugs that has exploded in popularity in the past year.

The results of two clinical trials, presented here at the 2023 American Diabetes Association Scientific Sessions, point to the progress pharmaceutical companies have made in developing a weight-loss drug in pill form.

Popular drugs, including Eli Lilly’s Mounjaro and Novo Nordisk’s Ozempic and Wegovy, can produce significant weight loss, but all are given as weekly injections.

A daily pill form of weight loss medication may be a more palatable option for some people.

“The great thing about tablets is that pretty much everyone is used to taking a tablet for something, even if it’s just a vitamin. It’s not a big deal,” said Dr. Robert Gabbay, ADA’s chief scientist.

On Sunday, Novo Nordisk presented findings testing an oral version of semaglutide, the active ingredient in Ozempic and Wegovy, for weight loss in people who are obese or overweight and who do not have type 2 diabetes. Participants in the clinical trial of Phase 3 patients lost 15% of their body weight, on average, after 68 weeks. The findings were simultaneously published in The Lancet.

The weight loss observed in the trial was on par with what Novo Nordisk reported in clinical trials with people who received a weekly injection of semaglutide for the same period of time.

“It really is a game changer,” Gabbay said.

Some people prefer to take their medicine in pill or tablet form, rather than an injection, because they are afraid of needles, he said.

Dr. Mico Guevarra, who leads oral semaglutide research for Novo Nordisk, told NBC News that an oral weight-loss medication would give people more choice.

“The goal right now is to push for individualized treatment,” he said. “It really depends on the goal of the patient, the goal of the doctor as well, and sticking to that and having options as to what they would like and what would be best for them.”

An oral weight-loss drug may not be on the market this year. Erika Arcieri, a spokeswoman for Novo Nordisk, said the company planned to apply for Food and Drug Administration approval sometime in 2023.

More about weight loss drugs

A lower-dose version of oral semaglutide from Novo Nordisk, called Rybelsus, is already approved for type 2 diabetes.

The dose tested in the clinical trial for weight loss was higher. It’s similar to how Ozempic, which is a slightly lower dose of semaglutide, is approved for diabetes, while Wegovy, a higher dose of the drug, is approved for weight loss, Guevarra said.

Dr. Shauna Levy, an obesity medicine specialist at the Tulane Bariatric Center in New Orleans, agreed that an oral weight-loss drug would likely give people more choice and increase access, but the side effects side effects could be more serious than those seen with injections.

Patients taking Rybelsus, he said, tend to report more side effects compared with the injection, particularly nausea.

“What is the side effect profile?” asked Levy, who was not involved in the investigation.

Adherence is also a concern: Oral semaglutide is supposed to be taken daily, in the morning, on an empty stomach. “There are a lot of requirements,” she said.

Guevarra said that oral semaglutide was well tolerated and that the prevalence of side effects was similar to that of the injection. Nausea was the most common side effect reported, she said. Overall, 80% of people who received the oral drug reported gastrointestinal problems, which were described as mild to moderate, compared with 46% of people in the placebo group. About 6% of people chose to stop taking the drug before the trial ended because of side effects.

Regardless, pharmaceutical industry researchers say oral weight-loss drugs have their place.

“Patients with obesity, in my experience, have had different preferences,” said Dr. Nadia Ahmad, a physician who leads Eli Lilly’s clinical obesity research.

Lilly presented the results of an oral weight-loss drug at Friday’s conference. Participants taking the drug, called orforlipron, lost an average of 9.4% to 14.7% of their body weight, depending on the dose administered, after 36 weeks, according to results from the phase 2 clinical trial, which were published in the New England Journal of Medicine.

The efficacy is “comparable to approved GLP-1s,” said study lead author Dr. Sean Wharton, a weight loss specialist at the Wharton Medical Clinic, who focuses on weight loss and blood pressure control. diabetes in Burlington, Ontario, who presented the findings Friday.

Like oral semaglutide, orforlipron is taken every day, in the morning, Wharton said. Unlike oral semaglutide, however, orforlipron can be taken within 30 minutes of eating.

Lilly is launching a Phase 3 clinical trial to test orforlipron, according to clinical trials.gov.

So far, none of the oral weight loss drugs have shown as high efficacy as Lilly’s tirzepatide, which was shown to reduce body weight, on average, by 22.5% after 72 weeks.

Gabbay said the weight loss shown is still significant.

“I think we’ve messed up a bit,” he said, “because a few years ago we didn’t have anything as effective.”

Continue NBC HEALTH in Twitter & Facebook.

By Mitchell G. Patton

You May Also Like